4 Feb 2009 12:32
| For Immediate Release | 4 February 2009 |
ImmuPharma PLC
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, granted today share options to certain of its employees and Directors. The Company has adopted a HM Revenue & Customs approved share ownership plan (CSOP) and an unapproved share option scheme.
The amount of options granted are summarised in the following table:
| Director | Options Granted |
| Richard Warr | 140,000 |
| Robert Zimmer | 150,000 |
| Dimitri Dimitriou | 140,000 |
| Franco di Muzio | 100,000 |
| Ajay Agrawal | 100,000 |
The share options provide the right to subscribe for ordinary shares of 10 pence each in the Company at a price of 86.5 pence each, the closing middle market price on 3 February 2009. The options are exercisable between 3 years and 10 years from the date of grant.
For further information, please contact:
ImmuPharma PLC
Dimitri Dimitriou, Chief Executive Officer 020 7152 4080
Richard Warr, Chairman 020 7152 4080
Dr Robert Zimmer, President & Chief Scientific Officer +33 389 32 76 50
Panmure Gordon & Co (Nominated Advisor and Broker)
Andrew Burnett / Rakesh Sharma (Corporate Finance) 020 7459 3600
Ashton Clanfield (Corporate Broking)
Buchanan Communications 020 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich
Immupharma (IMM)